Q-omics provides the consensus-scored B4GALNT4 profile across patient tissues and cancer cell-line models. B4GALNT4 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, B4GALNT4 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, B4GALNT4 RNA expression shows 16,714 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where B4GALNT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B4GALNT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B4GALNT4 survival associations across molecular data types. B4GALNT4 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B4GALNT4 RNA expression–survival associations across cancer types. High B4GALNT4 expression shows unfavorable associations in KIRC, KIRP, ACC, MESO and UVM, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for B4GALNT4 RNA expression.
This table summarizes B4GALNT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for B4GALNT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B4GALNT4 shows higher tumor expression in LUAD, COAD, BLCA, KIRC, LUSC and BRCA. The LUAD box plot shows higher B4GALNT4 RNA expression in tumor versus normal tissue (log2 FC = +2.035, t-test p < 0.001).
This table shows molecular features associated with B4GALNT4 in patient tissues and cancer cell lines. In patient samples, B4GALNT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, B4GALNT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
